期刊文献+

抗痛风药非布司他的合成方法研究进展 被引量:2

Analysis of the Synthesis Method about Anti-gout Drug Febuxostat
下载PDF
导出
摘要 文章总结了抗痛风新药——非布司他的合成方法,通过不同合成路线、操作方式的分析和比较,发现目前研究的热点在于对工艺中剧毒、强腐蚀性的试剂进行替换,以及对反应设备、反应条件的改进。文章希望通过对该药物的合成方法进行综述,为我国医药企业改进这一药物的合成路线,寻找更加绿色、环保、可工业化生产的方法提供研究思路和参考。 The article summarizes the synthesis method about the anti-gout drug febuxostat. Present study is focus on how to replace the highly toxic reagent and strong corrosive reagent in the reaction, and how to improve the reaction equipment and the reaction conditions. The article summarizes the synthesis methods of febuxostat in order to provide more reference on improving synthesis route, looking lbr green, environmental friendly and industrial manufacture methods.
出处 《广东化工》 CAS 2017年第1期64-65,共2页 Guangdong Chemical Industry
关键词 非布司他 合成 绿色环保 进展 febuxostat;synthesis;green;environmental methods
  • 相关文献

参考文献3

二级参考文献33

  • 1Yu KH. Febuxostat : a novel non-purlne selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout[ J]. Recent Pat lnflamm Allergy Drug Discov,2007,1 ( 1 ) :69-75.
  • 2Mayer M, Khosravan DR. Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment [ J ]. Am J Ther,2005,12 ( 1 ) :22-34.
  • 3Lustberg, ME. Febuxostat versus allopurinol for gout [ J ]. N Engl J Med, 2006, 354(14) :1532-1533.
  • 4Schumacher H R, Becker MA. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout : a 28 -week, phase Ⅲ, randomized, double-blind, parallel-group trial [ J ]. Arthitis Rheum, 2008,59( 11 ) :1540-1548.
  • 5Khosravan R J, Wu T. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs[ J]. J Clin Pharmacol,2006,46(8) :855-866.
  • 6Schumacher HR, Becker MA. Febuxostat in the treatment of gout :5-y findings of the FOCUS efficacy and safety study [ J ]. Rheumatology ( Oxford), 2009,48 (2) : 188-194.
  • 7Bruce SP. Febuxostat:a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout[ J]. Ann Pharmacothe,2006,40(12) :2187-2194.
  • 8Mukoyoshi M, Nishimura S. In vitro drug-drug interaction studies with febux- ostat, a novel non-purine selective inhibitor of xanthine oxidase : plasma protein binding,identification of metabolic enzymes and cytochome P450 inhibition[ J]. Xenobiotica ,2008,38 ( 5 ) :496-510.
  • 9Alfonso Gutiérrez-Maclas,EValizarralde-Palaeios,Pedro Martínez-Odriozola.Fatal allopurinol hypersensitivity syndrome after treatment of a-symptomatic hyperuricaemia[J].BMJ,2005,331:623-624.
  • 10Tausche AK,Aringer M,Schroeder HE.The Janus Faces of Allopurinol-Allopurinol hypersensitivity syndrome[J].Am J Med,2008,121:e3-e4.

共引文献13

同被引文献11

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部